Ocaliva was supposed to protect your liver. Instead, for many, it destroyed it.
Ocaliva was sold as a treatment for primary biliary cholangitis, a chronic disease that damages the bile ducts in the liver. It came to market with promise. It left the market under a cloud of serious liver injury, transplant, and death.
By late 2025, the FDA had withdrawn approval of Ocaliva after concluding the postmarketing evidence showed excess liver transplants and deaths and did not verify the clinical benefit the company needed to prove. Intercept then pulled the drug from the United States market.











